Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (693)	7/30/1998 2:54:00 PM
From: Richard Huth	Read Replies (1) \| Respond to of 3202

Well, let's resist together than - and stay long. If rkrw has any bad experience with XOMA, well, sorry for the losses, but if Incyte get's money out of it, the deal is ok. And who else would have been around paying for the patents. Incyte would never have used them, and given the strong patent situation at XOMA, no one else, too. As a shareholder I like receiving money for otherwise useless things. Instead of complaining we all should be happy about an extra revenue - Incyte not only got options but cash (so rkrw should not complain that much about his past problems with XOMA). There is one other thing that keeps stock price down. Some analysts fear (look at big head at DMG), that royalties won't come in because Incyte would never be able to prove that a drug is based on Incyte's databases. But this is not true. Whenever a company might find a component matching a gene, they will know it, because the company is asking for additional material. So we just have to wait, let others work and risk their money, and take the profit from the successful. Was there anyone talking of a money machine to come? VBG As a radio reporter I would say: Stay with us, see you after the break! - getting rich is better than throwing the towel to quickly only because one cannot stand the heat of being an investor in the roller coaster biotech.